Original Articles

You have full text access to this OnlineOpen article

Quality assurance, efficiency indicators and cost-utility of the evaluation workup for liver transplantation

  1. Paolo De Simone,
  2. Paola Carrai,
  3. Lidiana Baldoni,
  4. Stefania Petruccelli,
  5. Laura Coletti,
  6. Luca Morelli,
  7. Franco Filipponi†,*

Article first published online: 25 AUG 2005

DOI: 10.1002/lt.20484

Issue

Liver Transplantation

Liver Transplantation

Volume 11, Issue 9, pages 1080–1085, September 2005

Additional Information

How to Cite

De Simone, P., Carrai, P., Baldoni, L., Petruccelli, S., Coletti, L., Morelli, L. and Filipponi, F. (2005), Quality assurance, efficiency indicators and cost-utility of the evaluation workup for liver transplantation. Liver Transpl, 11: 1080–1085. doi: 10.1002/lt.20484

Author Information

  1. Liver Transplant Unit, University of Pisa, Cisanello Hospital, Pisa, Italy

  1. †

    Telephone 39-050-99-54-21; Fax: 39-050-99-54-20

*Liver Transplant Unit, Cisanello Hospital, Via Paradisa, 2, 56124, Pisa, Italy

  1. †

    Telephone 39-050-99-54-21; Fax: 39-050-99-54-20

Publication History

  1. Issue published online: 25 AUG 2005
  2. Article first published online: 25 AUG 2005
  3. Manuscript Accepted: 19 APR 2005
  4. Manuscript Received: 1 APR 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (126K)

References

  • 1
    Rufat P, Fourquet F, Conti F, Le Gales C, Houssin D, Coste J. Costs and outcomes of liver transplantation in adults: a prospective, 1-year, follow-up study. GRETHECO study group. Transplantation 1999; 68: 76–83.
  • 2
    Best JH, Veenstra DL, Geppert J. Trends in expenditures for Medicare liver transplant recipients. Liver Transpl 2001; 7: 858–862.
    Direct Link:
  • 3
    van Agthoven M, Metselaar HJ, Tilanus HW, de Man RA, IJzermans JN, Martin van Ineveld BM. A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure. Transpl Int 2001; 14: 87–94.
  • 4
    Sagmeister M, Mullhaupt B, Kadry Z, Kullak-Ublick GA, Clavien PA, Renner EL. Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation. 2002; 73: 616–622.
  • 5
    Skeie B, Mishra V, Vaaler S, Amlie E. A comparison of actual cost, DRG-based cost, and hospital reimbursement for liver transplant patients. Transpl Int 2002; 15: 439–445.
    Direct Link:
  • 6
    Taylor MC, Greig PD, Detsky AS, McLeod RS, Abdoh A, Krahn MD. Factors associated with the high cost of liver transplantation in adults. Can J Surg 2002; 45: 425–434.
  • 7
    Filipponi F, Pisati R, Cavicchini G, Ulivieri MI, Ferrara R, Mosca F. Cost and outcome analysis and cost determinants of liver transplantation in a European National Health Service hospital. Transplantation 2003; 75: 1731–1736.
  • 8
    Longworth L, Young T, Buxton MJ, Ratcliffe J, Neuberger J, Burroughs A, Bryan S, CELT Project Team. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transpl 2003; 9: 1295–1307.
    Direct Link:
  • 9
    Russo MW, Brown JrRS. Financial impact of adult living donation. Liver Transpl 2003; 9(10 Suppl 2 ): S12–S15.
    Direct Link:
  • 10
    Trotter JF, Mackenzie S, Wachs M, Bak T, Steinberg T, Polsky P, et al. Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation. Transplantation 2003; 75: 473–476.
  • 11
    Russo MW, Brown JrRS. Is the cost of adult living donor liver transplantation higher than deceased donor liver transplantation? Liver Transpl 2004; 10: 467–468.
    Direct Link:
  • 12
    Hollenbeak CS, Alfrey EJ, Sheridan K, Burger TL, Dillon PW. Surgical site infections following pediatric liver transplantation: risks and costs. Transpl Infect Dis 2003; 5: 72–78.
    Direct Link:
  • 13
    Cole CR, Bucuvalas JC, Hornung R, Ryckman FC, Alonso MP, Balistreri WF, Kotagal U. Outcome after pediatric liver transplantation impact of living donor transplantation on cost. J Pediatr 2004; 144: 729–735.
  • 14
    Kusne S, Grossi P, Irish W, St George K, Rinaldo C, Rakela J, Fung J. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 1125–1131.
  • 15
    Das A. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients. Hepatology 2000; 31: 311–317.
    Direct Link:
  • 16
    Kim WR, Badley AD, Wiesner RH, Porayko MK, Seaberg EC, Keating MR, et al. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation 2000; 69: 357–361.
  • 17
    Vanness DJ, Kim WR. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. Health Econ 2002; 11: 551–566.
    Direct Link:
  • 18
    Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741–748.
    Direct Link:
  • 19
    Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9: 182–187.
    Direct Link:
  • 20
    Zoulim F. Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation? J Hepatol 2003; 38: 850–852.
  • 21
    Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003; 17: 254–258.
    Direct Link:
  • 22
    Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203–1208.
  • 23
    Azoulay D, Linhares MM, Huguet E, Delvart V, Castaing D, Adam R, et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 2002; 236: 713–721.
  • 24
    Saab S, Ly D, Han SB, Lin RK, Rojter SE, Ghobrial RM, Busuttil RW. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002; 8: 449–457.
    Direct Link:
  • 25
    Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073–1079.
    Direct Link:
  • 26
    Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251–259.
  • 27
    Wolf DC. Screening for hepatocellular carcinoma: is it cost-effective? Liver Transpl 2003; 9: 682–683.
    Direct Link:
  • 28
    Shimoda M, Saab S, Morrisey M, Ghobrial RM, Farmer DG, Chen P, et al. A cost-effectiveness analysis of biliary anastomosis with or without T-tube after orthotopic liver transplantation. Am J Transplant 2001; 1: 157–161.
    Direct Link:
  • 29
    Nair S, Cohen DB, Cohen MP, Tan H, Maley W, Thuluvath PJ. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 2001; 96: 842–845.
    Direct Link:
  • 30
    Talwalkar JA, Seaberg E, Kim WR, Wiesner RH. Predicting clinical and economic outcomes after liver transplantation using the Mayo primary sclerosing cholangitis model and Child-Pugh score. National Institutes of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database Group. Liver Transpl 2000; 6: 753–758.
    Direct Link:
  • 31
    Abouljoud MS, Brown KA, May E, Baliad P, Escobar FS, Mozes MF. Cost-effective management of acute rejection in liver transplant recipients: a managed care perspective. Transplant Proc 1997; 29: 1557–1559.
  • 32
    Lake JR, Gorman KJ, Esquivel CO, Wiesner RH, Klintmalm GB, Miller CM, et al. The impact of immunosuppressive regimens on the cost of liver transplantation—results from the U.S. FK506 multicenter trial. Transplantation 1995; 60: 1089–1095.
  • 33
    Coukell AJ, Plosker GL. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Pharmacoeconomics 1998; 14: 691–708.
  • 34
    Merritt WT. Practice patterns and anesthesia-related costs for liver transplantation. Liver Transpl Surg 1997; 3: 449–450.
    Direct Link:
  • 35
    Biancofiore G, Bindi L, Cellai F, Consani G, Meacci I, Boggi U, et al. Orthotopic liver transplant. Analysis of costs related to anesthesiologic and intensive care phases. Minerva Anestesiol 1998; 64: 587–591.
  • 36
    Istituto Nazionale di Statistica (ISTAT). Homepage. Available at: http://www.istat.it. Accessed: June 20, 2005.
  • 37
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699.
View Full Article (HTML) Get PDF (126K)